Trastuzumab emtansine for HER2-positive advanced breast cancer.
N Engl J Med. 2012 Nov 8;367(19):1783-91.
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
N Engl J Med. 2020 Feb 13;382(7):597-609.
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer:
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.
J Clin Oncol. 2020 Sep 20; 38(27): 3138–3149.
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
N Engl J Med. 2012 Jan 12;366(2):109-19.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Oncol. 2013 May;14(6):461-71.
Ann Oncol. 2020 Sep;31(9):1223-1230.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol. 2017 Dec;18(12):1688-1700.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
N Engl J Med. 2017 Jul 13;377(2):122-131.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
N Engl J Med. 2020 Feb 13;382(7):610-621.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
N Engl J Med. 2022 Mar 24;386(12):1143-1154.